| Octreotide Acetate | Chiesi U.S.A | ||
| 20 mg ; Delayed-release Capsules |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| None | None | ||
| MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. | |||
|
Yes
| |||
| Mycapssa | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* (***** ****** ******) |
| ****** ** ******** ******** | ****** ** ******** ******** | ****** ** ******** ******** | **** ********** ******* *** ************* ******* | ****** ** ******** ******** | ****** ** ******** ******** | ****** ** ******** ******** | **** ********** ******* *** ************* ******* | ************** ************ *** ******* ******* ** ******** | ************** ************ *** ******* ******* ** ******** | ************** ************ *** ******* ******* ** ******** | ************** ************ *** ******* ******* ** ******** | ************** ************ *** ******* ******* ** ******** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| **** | *** \ ********* | *** **, **** | ******* | **** | ******* *** **** *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|